UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
American journal of clinical dermatology, ISSN 1175-0561, 06/2016, Volume 17, Issue 3, pp. 201 - 223
Life Sciences & Biomedicine | Dermatology | Science & Technology | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Adjuvants, Immunologic - administration & dosage | Cell Proliferation | Fibroblasts - physiology | Keloid - etiology | Humans | Aminoquinolines - administration & dosage | Antibiotics, Antineoplastic - adverse effects | Antimetabolites - therapeutic use | Cicatrix, Hypertrophic - pathology | Adjuvants, Immunologic - adverse effects | Fluorouracil - therapeutic use | Inflammation - metabolism | Anti-Inflammatory Agents - adverse effects | Fluorouracil - administration & dosage | Bleomycin - therapeutic use | Fluorouracil - adverse effects | Extracellular Matrix - physiology | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Laser Therapy - methods | Adjuvants, Immunologic - therapeutic use | Glucocorticoids - adverse effects | Cicatrix, Hypertrophic - etiology | Keloid - pathology | Keloid - therapy | Clinical Trials as Topic | Bleomycin - administration & dosage | Bleomycin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites - administration & dosage | Antimetabolites - adverse effects | Collagen - metabolism | Antibiotics, Antineoplastic - therapeutic use | Cicatrix, Hypertrophic - therapy | Combined Modality Therapy - methods | Wound Healing - physiology | Cryotherapy - methods | Aminoquinolines - therapeutic use | Aminoquinolines - adverse effects
Journal Article
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 12/2016, Volume 60, Issue 12, pp. 7321 - 7332
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Ethanolamines - adverse effects | Artemisinins - pharmacokinetics | Humans | Middle Aged | Half-Life | Male | Healthy Volunteers | Quinolines - pharmacokinetics | Young Adult | Ethanolamines - pharmacokinetics | Drug Interactions | Adult | Female | Fluorenes - adverse effects | Drug Therapy, Combination | Antimalarials - adverse effects | Fluorenes - pharmacokinetics | Antimalarials - pharmacokinetics | Plasmodium vivax - drug effects | Malaria, Vivax - drug therapy | Adolescent | Aged | Aminoquinolines - pharmacokinetics | Artemisinins - adverse effects | Quinolines - adverse effects | Aminoquinolines - adverse effects | Index Medicus
Journal Article
Life sciences (1973), ISSN 0024-3205, 08/2020, Volume 254, pp. 117775 - 10
COVID-19 | Anti-viral mechanism | Hydroxychloroquine | Safety | Chloroquine | Aminoquinolines | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Hydroxychloroquine - therapeutic use | Pandemics | Antiviral Agents - therapeutic use | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Betacoronavirus - drug effects | Chloroquine - therapeutic use | Treatment Outcome | Clinical Trials as Topic | Drug Repositioning | Hydroxychloroquine - adverse effects | Chloroquine - adverse effects | Randomized Controlled Trials as Topic | SARS-CoV-2 | Antiviral Agents - adverse effects | Aminoquinolines - therapeutic use | Aminoquinolines - adverse effects | Antiviral agents | Side effects | Toxicity | Viral diseases | Clinical trials | Coronaviruses | Index Medicus
Journal Article
British journal of dermatology (1951), ISSN 0007-0963, 12/2007, Volume 157, Issue s2, pp. 34 - 40
5-fluorouracil | actinic keratoses | comparative study | cryosurgery | imiquimod | field cancerisation | 5‐fluorouracil | Field cancerisation | 5-Fluorouracil | Cryosurgery | Actinic keratoses | Imiquimod | Comparative study | Life Sciences & Biomedicine | Dermatology | Science & Technology | Neoplasms, Radiation-Induced - surgery | Skin Neoplasms - drug therapy | Follow-Up Studies | Humans | Middle Aged | Carcinoma, Squamous Cell - surgery | Male | Antineoplastic Agents - therapeutic use | Keratosis - drug therapy | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Immunocompetence | Skin Neoplasms - surgery | Esthetics | Treatment Outcome | Neoplasms, Radiation-Induced - drug therapy | Ultraviolet Rays - adverse effects | Carcinoma, Squamous Cell - drug therapy | Aged | Cryosurgery - adverse effects | Aminoquinolines - therapeutic use | Aminoquinolines - adverse effects | Medical research | Algorithms | Surgery | Patient outcomes | Medicine, Experimental | Comparative analysis | Fluorouracil | Keratosis | Index Medicus
Journal Article
European journal of pharmacology, ISSN 0014-2999, 05/2018, Volume 826, pp. 31 - 38
Systemic exposure | Calcemic effect | Vitamin D receptor target gene | Skin atrophy | Psoriasis | Vitamin D3-containing ointment | Vitamin D | containing ointment | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Rats, Wistar | Calcium - metabolism | Imiquimod | Humans | Calcitriol - adverse effects | Aminoquinolines - toxicity | Male | Administration, Cutaneous | Dermatologic Agents - adverse effects | Calcitriol - analogs & derivatives | Calcium - blood | Rats, Hairless | Hypercalcemia - blood | Betamethasone - adverse effects | Psoriasis - blood | Ointments | Skin - pathology | Disease Models, Animal | Psoriasis - drug therapy | Betamethasone - analogs & derivatives | Rats | Hypercalcemia - chemically induced | Receptors, Calcitriol - metabolism | Animals | Dihydroxycholecalciferols - adverse effects | Psoriasis - chemically induced | Atrophy - blood | Atrophy - chemically induced | Clobetasol - adverse effects | Drug Combinations | Skin - drug effects | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 03/2019, Volume 30, Issue 3, pp. 447 - 455
Life Sciences & Biomedicine | Oncology | Science & Technology | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Aminoquinolines - administration & dosage | ErbB Receptors - genetics | Male | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - pathology | Afatinib - administration & dosage | ErbB Receptors - antagonists & inhibitors | Organoids - pathology | Carcinoma, Non-Small-Cell Lung - genetics | Mutation - genetics | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Acrylamides - administration & dosage | Organoids - drug effects | Cell Line, Tumor | Aged | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Acrylamides - adverse effects | Aminoquinolines - adverse effects | Index Medicus
Journal Article
Nature communications, ISSN 2041-1723, 09/2015, Volume 6, Issue 1, pp. 8424 - 8424
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Animals, Newborn | Disease Susceptibility | Psoriasis - drug therapy | Imiquimod | Polymyxin B - adverse effects | Mice, Inbred C57BL | Microbiota - drug effects | Interleukins - metabolism | Vancomycin - adverse effects | Interleukin-17 - metabolism | Animals | Drug Interactions | T-Lymphocytes - metabolism | Psoriasis - chemically induced | Psoriasis - metabolism | Anti-Bacterial Agents - adverse effects | Mice | Aminoquinolines | Skin - immunology | Index Medicus
Journal Article
Annales de dermatologie et de vénéréologie, ISSN 0151-9638, 01/2015, Volume 142, Issue 1, pp. 78 - 79
Journal Article
Cancer immunology research, ISSN 2326-6066, 12/2013, Volume 1, Issue 6, pp. 373 - 377
vemurafenib | anti-PD-1 | immunotherapy | Melanoma | Oncology | Immunology | Life Sciences & Biomedicine | Science & Technology | Drug Eruptions - etiology | Guillain-Barre Syndrome - chemically induced | Skin Neoplasms - drug therapy | Humans | Middle Aged | Aminoquinolines - administration & dosage | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Indoles - administration & dosage | Indoles - adverse effects | Anaphylaxis - chemically induced | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Sulfonamides - adverse effects | Adult | Female | Sulfonamides - administration & dosage | Aminoquinolines - adverse effects | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 3, pp. 229 - 241
Prospective Studies | Humans | Aminoquinolines - administration & dosage | Male | Parasitemia - drug therapy | Secondary Prevention - methods | Primaquine - administration & dosage | Malaria, Vivax - complications | Adult | Female | Drug Therapy, Combination | Antimalarials - adverse effects | Double-Blind Method | Kaplan-Meier Estimate | Chloroquine - therapeutic use | Glucosephosphate Dehydrogenase Deficiency - complications | Disease-Free Survival | Antimalarials - administration & dosage | Malaria, Vivax - drug therapy | Adolescent | Plasmodium vivax - isolation & purification | Glucosephosphate Dehydrogenase - metabolism | Primaquine - adverse effects | Hemoglobins - analysis | Aminoquinolines - adverse effects | Tafenoquine | Prevention | Plasmodium vivax | Malaria | Primaquine | Analysis | Clinical trials | Hemoglobin | Dosage and administration | Research | Comparative analysis | Drug therapy | Health care | Enzymes | Chloroquine | Patients | Disease prevention | Glucose dehydrogenase | Enzymatic activity | Product development | Glucosephosphate dehydrogenase | Parasitemia | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article